Biologics Contract Development Market Report 2026

The biologics contract development market size has grown rapidly in recent years. It will grow from $8.55 billion in 2025 to $9.53 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing biologics pipeline complexity, rising costs of in-house manufacturing, expansion of monoclonal antibody development, growth of early-stage biologics research, increasing reliance on specialized cdmos.

The biologics contract development market size is expected to see rapid growth in the next few years. It will grow to $14.46 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing demand for rapid biologics scale-up, rising investments in advanced mammalian cell platforms, expansion of oncology biologics pipelines, growing focus on flexible manufacturing capacity, increasing adoption of digital bioprocess optimization. Major trends in the forecast period include increasing outsourcing of biologics process development, rising demand for scalable cell line development, growing adoption of single-use bioprocessing systems, expansion of integrated cdmo service models, enhanced focus on speed-to-clinic development.

The increasing prevalence of chronic diseases is expected to drive the growth of the biologics contract development market in the coming years. Chronic diseases are illnesses that persist for a year or longer and require ongoing medical care. The rising number of chronic disease cases is boosting the need for the development of new drugs, including biologics, thereby supporting the expansion of the biologics contract development market. For example, in September 2024, according to reports published by the Office for Health Improvement & Disparities, a UK-based government agency, the first half of 2023 saw 3,940 excess deaths due to chronic lower respiratory diseases, representing a 30% increase compared to expected rates. For the full year, this figure rose to 5,363, reflecting a 22% overall increase. Hence, the growing prevalence of chronic diseases is expected to propel the biologics contract development market.

Major companies operating in biologics contract development are concentrating on incorporating data analytics into the biologics development process. These companies are adopting digital technologies and data analytics in biologics development to improve process monitoring, data evaluation, and decision-making, thereby enhancing efficiency and productivity. For example, in October 2023, WuXi Biologics, a China-based biologics contract development and manufacturing company, introduced its WuXiUI high-productivity bioprocessing platform. WuXiUI is WuXi Biologics’ proprietary ultra-intensified intermittent-perfusion fed-batch platform, which has been successfully developed and applied internally as well as in client-facing biologics development and manufacturing projects. It enables real-time monitoring of critical process parameters through integrated Process Analytical Technology tools, optimization of cell culture productivity, and prediction of product quality and yield profiles under varying process conditions, given appropriate process data inputs.

In October 2024, Lonza, a Switzerland-based provider of biologics contract development and manufacturing services, acquired the Genentech large-scale biologics manufacturing site in Vacaville, California, US, from Roche for USD $1.2 billion. Through this acquisition, Lonza aims to expand its U.S. biologics manufacturing presence, enhance large-scale mammalian production capacity, and strengthen its end-to-end CDMO offerings for external clients. The Genentech Vacaville biologics manufacturing facility is a US-based provider of large-scale mammalian biologics production services, including clinical- and commercial-scale manufacturing as well as fill/finish capabilities.

Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, Yposkesi.

North America was the largest region in the biologics contract development market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics contract development market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the biologics contract development market by increasing costs of imported bioreactors, single-use consumables, process control systems, and specialized raw materials. North America and Europe are most affected due to dependence on imported bioprocessing equipment, while Asia-Pacific faces higher costs for export-oriented development services. These tariffs are raising development expenses and project timelines. However, they are also encouraging domestic capacity expansion, regional sourcing of bioprocess inputs, and investments in localized biologics development infrastructure.

The biologics contract development market research report is one of a series of new reports that provides biologics contract development market statistics, including biologics contract development industry global market size, regional shares, competitors with a biologics contract development market share, detailed biologics contract development market segments, market trends and opportunities, and any further data you may need to thrive in the biologics contract development industry. This biologics contract development market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics contract development involves companies that offer biologics development and manufacturing services to pharmaceutical firms on a contractual basis. This approach allows pharmaceutical companies to outsource the production of biologics, enabling them to focus on marketing, research and development, and product branding.

The primary sources for biologics contract development include microbial, mammalian, and other origins. Microbial sources are utilized for producing various biologics. The indications for biologics contract development include oncology, immunological disorders, cardiovascular disorders, hematological disorders, and other conditions, which are applied in product services such as cell line development, process development, and additional related services.

The biologics contract development market includes revenues earned by entities by sourcing, solid and specialized formulation development, and process analytics development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.